News & Updates
Filter by Specialty:
Muscle mass influences paclitaxel systemic exposure, informs personalized dosing
Extending the infusion duration of paclitaxel in breast cancer patients with low skeletal muscle area is expected to reduce peripheral neuropathy while maintaining systemic exposure, suggests a study.
Muscle mass influences paclitaxel systemic exposure, informs personalized dosing
29 Jun 2022
Updated ASCEMBL results boost asciminib potential for CML
In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).
Updated ASCEMBL results boost asciminib potential for CML
28 Jun 2022
PPIs raise death risk in advanced NSCLC patients on antitumour therapy
Treatment with proton pump inhibitors (PPI) appears to increase the risk of mortality among patients with advanced nonsmall cell lung cancer (NSCLC) undergoing systemic antitumour therapy, reveals a recent study.
PPIs raise death risk in advanced NSCLC patients on antitumour therapy
25 Jun 2022
KangDuo Surgical Robot-01 system feasible for robot-assisted radical prostatectomy
Use of the KangDuo Surgical Robot-01 (KD-SR-01) system for the management of localized prostate cancer is safe and effective, according to the initial results of a prospective, single-centre study.